SBTX
NASDAQSilverback Therapeutics Inc.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- INSIDERLowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Karas Eric4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERTanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Dorsey Brian4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Chakma Justin4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Scott Kathleen D.4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4 filed by Fitzpatrick Alexander A4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- SECSEC Form 10-Q filed by Silverback Therapeutics Inc.10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- SECSilverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- INSIDERFitzpatrick Alexander A bought $319,954 worth of shares (86,258 units at $3.71), increasing direct ownership by 2,905% to 89,227 units (SEC Form 4)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- SECSilverback Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- SECSilverback Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- INSIDERSEC Form 4: Shawver Laura exercised 100,000 shares at a strike of $1.27 and sold $770,520 worth of shares (100,000 units at $7.71)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- SECSEC Form 144 filed by Silverback Therapeutics Inc.144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- INSIDERSEC Form 4: Ra Capital Management, L.P. bought $23,250,000 worth of shares (3,750,000 units at $6.20)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- INSIDERSEC Form 4: Orbimed Advisors Llc bought $3,100,000 worth of shares (500,000 units at $6.20)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- 13D/GSEC Form SC 13D filed by Silverback Therapeutics Inc.SC 13D - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
- INSIDERSEC Form 4: Thompson Peter A. bought $3,100,000 worth of shares (500,000 units at $6.20)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
- SECSEC Form 10-Q filed by Silverback Therapeutics Inc.10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- SECSilverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
- INSIDERSEC Form 4: Shawver Laura exercised 45,004 shares at a strike of $1.27 and sold $316,489 worth of shares (45,004 units at $7.03)4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
SBTX FAQ
7 questionsWhat does Silverback Therapeutics Inc. do?
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody...Where does SBTX stock trade?
Silverback Therapeutics Inc. (SBTX) is listed on NASDAQ.What sector and industry is SBTX in?
Silverback Therapeutics Inc. operates in the Consumer Discretionary sector, Specialty Chemicals industry.When did Silverback Therapeutics Inc. go public?
Silverback Therapeutics Inc. (SBTX) completed its IPO in 2020.What are analysts saying about SBTX?
Silverback Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $350.00 price target on 2022-04-04.What companies are similar to SBTX?
Notable peers in the same industry include KVUE (Kenvue Inc.), CSL (Carlisle Companies Incorporated), CLX (Clorox Company), UNVR (Univar Solutions Inc.), DSEY (Diversey Holdings Ltd.). Compare SBTX side-by-side with any of them on Quantisnow.How can I track SBTX on Quantisnow?
Quantisnow aggregates Silverback Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SBTX to receive live email and push alerts on every new disclosure.